Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10
ConditionHealthy Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-50
SponsorFytexia
About this trial
This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg/m². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.
Eligibility criteria
Qualifiers
Healthy men and women aged 20 to 50 years.
Body Mass Index (BMI) of 18.5-24.9 kg/m² or 25.0-29.9 kg/m².
Stable use of permitted medications and/or dietary supplements during the study.
Individuals willing to maintain their usual dietary and physical activity habits throughout the study.
Disqualifiers
Individuals with known eating behavior disorders (verified using the Spanish version of the Adult Eating Behavior Questionnaire, AEBQ).
Subjects with a body weight gain or loss ≥10% within the previous 3 months.
Treatment with medications or dietary supplements for weight loss, satiety, or glucose control.
Individuals consuming protein powders or dietary supplements related to the objectives of the study.
Trial design
Treatments tested in this trial
- DNF-10: 250 mg/day
- Placebo: 250 mg maltodextrin/day
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fytexia
Lead sponsor
Centros de Investigación de Nutrición y Salud
Collaborator
Source ClinicalTrials.gov